irinotecan sucrosofate: Clinical Trials

45 trials of irinotecan sucrosofate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 8 recruiting, 6 not yet recruiting, 5 unknown. 45 Phase 1, 19 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 145Completed 18, Recruiting 8, Not yet recruiting 6, Unknown 5, Withdrawn 3, Active not recruiting 2, Terminated 2, Enrolling by invitation 1
Phase 219Recruiting 5, Not yet recruiting 4, Unknown 3, Withdrawn 3, Active not recruiting 1, Completed 1, Enrolling by invitation 1, Terminated 1

Follow irinotecan sucrosofate: new trials by email Literature Review of irinotecan sucrosofate trials Research Report on irinotecan sucrosofate

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies
Liposomal Irinotecan Plus Cisplatin - Advanced Solid Malignancies
Phase 1Not yet recruitingNational Health Research Institutes, Taiwan442026-12-012026-11-02
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months - Advanced Small Intestine Cancer, Appendiceal Cancers
Phase 1RecruitingThe Methodist Hospital Research Institute222026-09-182026-11-03
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic
Phase 1 / Phase 2RecruitingPeking University People's Hospital562026-03-052026-03-18
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites
Phase 1 / Phase 2RecruitingDong sheng Zhang482025-11-282026-02-09
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
nanoliposomal irinotecan plus carboplatin - GEP-NET
Phase 1 / Phase 2Enrolling by invitationNational Health Research Institutes, Taiwan522025-08-142025-08-15
Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors
Liposomal irinotecan in combination with vincristine and temozolomide - Solid Tumor Cancer
Phase 1Not yet recruitingYizhuo Zhang402024-12-012024-11-29
Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer
Irinotecan liposome(40mg/m2), Nab-paclitaxel, Gemcitabine - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingHarbin Medical University1322024-09-012024-07-22
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
Irinotecan Liposome, Bevacizumab - Metastatic Colorectal Cancer
Phase 1 / Phase 2UnknownWest China Hospital202024-08-092024-08-09
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Irinotecan liposoma, oxaliplatin, bevacizumab - Advanced Pancreatic Cancer (Part 1)
Phase 1 / Phase 2RecruitingDai, Guanghai1382024-06-232025-01-20
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer
Liposomal irinotecan, Bevacizumab - Colorectal Cancer
Phase 1 / Phase 2UnknownSun Yat-sen University742024-06-052024-05-30
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
JS001, JS004, JS007 - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingFudan University1172024-04-302024-04-17
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingBaohui Han802024-04-012024-03-27
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital962024-04-012024-03-15
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
nal-IRI /Experimental, Ramucirumab /Experimental, Trifluridine/Tipiracil /Experimental - Metastatic Gastric Adenocarcinoma, Second Line
Phase 1 / Phase 2RecruitingNational Health Research Institutes, Taiwan452024-04-012026-04-09
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Irinotecan Liposome, Oxaliplatin, 5-FU - Metastatic Colorectal Cancer
Phase 1UnknownShanghai Zhongshan Hospital782024-03-112024-03-19
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Mycophenolate Mofetil, Allopurinol, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma
Phase 1TerminatedWashington University School of Medicine172023-02-272024-12-05
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
PIPAC with Nal-IRI - Peritoneal Carcinomatosis, Peritoneal Metastases
Phase 1Active not recruitingUniversity Hospital, Ghent452022-11-212026-07-13
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU) - Pancreatic Cancer, Unresectable Pancreatic Cancer
Phase 1 / Phase 2WithdrawnDevalingam Mahalingam2022-09-132023-05-11
A Study of ASP3082 in Adults With Advanced Solid Tumors
Setidegrasib, Cetuximab, Leucovorin - Solid Tumor
Phase 1RecruitingAstellas Pharma Inc6812022-06-082026-10-14
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
Irinotecan liposome injection, Folinic Acid, 5-Fluorouracil - Metastatic Pancreatic Adenocarcinoma
Phase 1CompletedIpsen1772022-05-302025-04-30

Showing 20 of 45. Sign in to see all of them.

Conditions studied

Pancreatic Neoplasms (11)  ·  Colorectal Neoplasms (9)  ·  Neoplasms (6)  ·  Stomach Neoplasms (4)  ·  Osteosarcoma (3)  ·  Glioblastoma (2)  ·  Glioma (2)  ·  Neuroblastoma (2)  ·  Rhabdomyosarcoma (2)  ·  Sarcoma, Ewing (2)  ·  Small Cell Lung Carcinoma (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma, Mucinous (1)  ·  Adenoma, Islet Cell (1)  ·  Appendiceal Neoplasms (1)

Sponsors

National Health Research Institutes, Taiwan (3)  ·  Ipsen (2)  ·  PharmaEngine (2)  ·  University of California, San Francisco (2)  ·  Washington University School of Medicine (2)  ·  Academic and Community Cancer Research United (1)  ·  Andrew Hendifar, MD (1)  ·  Astellas Pharma Inc (1)  ·  Baohui Han (1)  ·  Baylor College of Medicine (1)  ·  Benaroya Research Institute (1)  ·  Brown University (1)  ·  CSPC Ouyi Pharmaceutical Co., Ltd. (1)  ·  Dai, Guanghai (1)  ·  Devalingam Mahalingam (1)

Countries

United States (23)  ·  China (10)  ·  Taiwan (4)  ·  France (3)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Japan (1)  ·  Portugal (1)  ·  Puerto Rico (1)  ·  South Korea (1)

Top investigators

Abdullah Esmail, MD (1)  ·  Afsaneh Barzi, MD (1)  ·  Andrew Hendifar, MD (1)  ·  Benoist Chibaudel, MD (1)  ·  Chia-Chi Lin, MD (1)  ·  Daniel Morgensztern, M.D. (1)  ·  Devalingam Mahalingam, MD (1)  ·  Erin K Barr, MD (1)  ·  Georgios Georgakis, MD (1)  ·  Howard Safran, MD (1)  ·  Hui-Jen Tsai, MD, PhD (1)  ·  Jihui Hao, Professor (1)  ·  Joseph Kim, MD (1)  ·  Kian-Huat Lim, M.D, Ph.D. (1)

Results publications

PMID 27871319, PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 19349540, PMID 22811849, PMID 23406728, PMID 23880820, PMID 25577133, PMID 26615328, PMID 27091418, PMID 31401903, PMID 33201358, PMID 33284237, PMID 36056179, PMID 36410913, PMID 36734848, PMID 37010988, PMID 39701097, PMID 39746964, PMID 40468090, PMID 41879829

NIH funding

2019 (1), P30CA014089 (1), P30CA015083 (1), R21CA186140 (1), ZIABC011078 (1)